HMGB1 and glioblastoma: In contrast, GBM cells treated with TMZ can release high-mobility group box 1 (HMGB1), which activates the NF-κB–NLRP3 inflammasome signaling axis in GAMs, thus promoting their differentiation into the M1 subtype (47, 48).